News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,281 Results
Type
Article (42296)
Company Profile (307)
Press Release (694659)
Multimedia
Podcasts (89)
Webinars (20)
Section
Business (207503)
Career Advice (2067)
Deals (35873)
Drug Delivery (126)
Drug Development (82326)
Employer Resources (175)
FDA (16518)
Job Trends (15146)
News (350733)
Policy (33042)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2613)
Accelerated approval (43)
Adcomms (25)
Allergies (164)
Alliances (50469)
ALS (196)
Alzheimer's disease (1758)
Antibody-drug conjugate (ADC) (375)
Approvals (16841)
Artificial intelligence (613)
Autoimmune disease (228)
Automation (51)
Bankruptcy (365)
Best Places to Work (11706)
BIOSECURE Act (21)
Biosimilars (205)
Biotechnology (209)
Bladder cancer (177)
Brain cancer (64)
Breast cancer (692)
Cancer (5392)
Cardiovascular disease (448)
Career advice (1753)
Career pathing (40)
CAR-T (305)
CDC (53)
Celiac Disease (2)
Cell therapy (820)
Cervical cancer (43)
Clinical research (70964)
Collaboration (1943)
Company closure (4)
Compensation (1297)
Complete response letters (70)
COVID-19 (2754)
CRISPR (103)
C-suite (1012)
Cystic fibrosis (149)
Data (7144)
Decentralized trials (3)
Denatured (26)
Depression (158)
Dermatology (61)
Diabetes (552)
Diagnostics (6871)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (301)
Drug pricing (197)
Drug shortages (30)
Duchenne muscular dystrophy (266)
Earnings (91629)
Editorial (62)
Employer branding (21)
Employer resources (154)
Events (121461)
Executive appointments (1053)
FDA (19987)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (32)
Funding (1654)
Gene editing (217)
Generative AI (56)
Gene therapy (673)
GLP-1 (1022)
Government (4728)
Grass and pollen (6)
Guidances (398)
Healthcare (19033)
HIV (74)
Huntington's disease (53)
IgA nephropathy (91)
Immunology and inflammation (274)
Immuno-oncology (84)
Indications (159)
Infectious disease (3071)
Inflammatory bowel disease (202)
Inflation Reduction Act (14)
Influenza (131)
Intellectual property (279)
Interviews (320)
IPO (16766)
IRA (50)
Job creations (3761)
Job search strategy (1462)
JPM (58)
Kidney cancer (18)
Labor market (92)
Layoffs (556)
Leadership (36)
Legal (8026)
Liver cancer (98)
Longevity (29)
Lung cancer (722)
Lymphoma (409)
Machine learning (54)
Management (59)
Manufacturing (945)
MASH (177)
Medical device (13878)
Medtech (13955)
Mergers & acquisitions (20277)
Metabolic disorders (1420)
mRNA (175)
Multiple sclerosis (174)
NASH (17)
Neurodegenerative disease (387)
Neuropsychiatric disorders (98)
Neuroscience (3169)
Neurotech (1)
NextGen: Class of 2026 (6593)
Non-profit (4555)
Now hiring (74)
Obesity (669)
Opinion (288)
Ovarian cancer (187)
Pain (230)
Pancreatic cancer (260)
Parkinson's disease (344)
Partnered (33)
Patents (563)
Patient recruitment (604)
Peanut (61)
People (60354)
Pharmaceutical (63)
Pharmacy benefit managers (32)
Phase 1 (22202)
Phase 2 (31288)
Phase 3 (23145)
Pipeline (7244)
Policy (305)
Postmarket research (2573)
Preclinical (9435)
Press Release (71)
Prostate cancer (278)
Psychedelics (49)
Radiopharmaceuticals (306)
Rare diseases (1007)
Real estate (6123)
Recruiting (72)
Regulatory (25221)
Reports (54)
Research institute (2439)
Resumes & cover letters (358)
Rett syndrome (33)
RNA editing (17)
RSV (86)
Schizophrenia (164)
Series A (276)
Series B (209)
Service/supplier (11)
Sickle cell disease (110)
Special edition (23)
Spinal muscular atrophy (164)
Sponsored (45)
Startups (3734)
State (2)
Stomach cancer (18)
Supply chain (121)
Tariffs (88)
The Weekly (61)
Vaccines (1064)
Venture capital (101)
Weight loss (426)
Women's health (112)
Worklife (19)
Date
Today (119)
Last 7 days (551)
Last 30 days (2634)
Last 365 days (30434)
2026 (8401)
2025 (30612)
2024 (35630)
2023 (40430)
2022 (51639)
2021 (56111)
2020 (54480)
2019 (46909)
2018 (35347)
2017 (32525)
2016 (32053)
2015 (38032)
2014 (31812)
2013 (26847)
2012 (29162)
2011 (29834)
2010 (27936)
Location
Africa (768)
Alabama (91)
Alaska (7)
Arizona (335)
Arkansas (14)
Asia (40446)
Australia (6745)
California (12436)
Canada (3531)
China (1250)
Colorado (530)
Connecticut (532)
Delaware (372)
Europe (88067)
Florida (1865)
Georgia (400)
Hawaii (3)
Idaho (62)
Illinois (990)
India (82)
Indiana (564)
Iowa (23)
Japan (495)
Kansas (133)
Kentucky (46)
Louisiana (38)
Maine (73)
Maryland (1498)
Massachusetts (8938)
Michigan (349)
Minnesota (681)
Mississippi (6)
Missouri (140)
Montana (36)
Nebraska (29)
Nevada (136)
New Hampshire (83)
New Jersey (3312)
New Mexico (29)
New York (3291)
North Carolina (1602)
North Dakota (9)
Northern California (6162)
Ohio (370)
Oklahoma (22)
Oregon (41)
Pennsylvania (2512)
Puerto Rico (27)
Rhode Island (50)
South America (1152)
South Carolina (79)
South Dakota (1)
Southern California (4880)
Tennessee (199)
Texas (1954)
United States (44135)
Utah (376)
Vermont (1)
Virginia (295)
Washington D.C. (80)
Washington State (1008)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
737,281 Results for "adverum biotechnologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lilly to Acquire Adverum Biotechnologies
October 27, 2025
·
13 min read
Press Releases
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
December 10, 2025
·
4 min read
Press Releases
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
December 2, 2025
·
12 min read
Press Releases
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
August 12, 2025
·
10 min read
Press Releases
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 5, 2025
September 8, 2025
·
2 min read
Press Releases
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 7, 2025
·
1 min read
Press Releases
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
September 23, 2025
·
4 min read
Biotech Bay
Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
Adverum Biotechnologies, Inc. today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at TD Cowen’s Genetic Medicines & RNA Summit on Friday, June 21, 2024 at 10:00 a.m. ET.
June 18, 2024
·
1 min read
Deals
Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy
The cornerstone of the deal is Ixo-vec, an intravitreal gene therapy currently in Phase III development for wet age-related macular degeneration. Eli Lilly made another foray into genetic medicine in June, picking up Verve Therapeutics for up to $1.3 billion.
October 24, 2025
·
2 min read
·
Heather McKenzie
Biotech Bay
Adverum Biotechnologies to Participate in Upcoming May 2024 Investor Conferences
Adverum Biotechnologies, Inc., a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, announced that the company will present at the following upcoming investor conferences.
May 3, 2024
·
1 min read
1 of 73,729
Next
